| Market Cap | 1.35K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -134.8M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -97.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -99.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 38.95B | 52W Low Chg | - |
| Insider Own | - | ROA | -6,818.39% | Shares Float | - | Beta | 96.08 |
| Inst Own | 0.52% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00000 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 303,124 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 300,000 | Change | 0.00% |
Medican Enterprises, Inc., a bio-pharmaceutical company, focuses on pursuing business opportunities in the medical and recreational marijuana sector. The company intends to invest in business of growing, marketing, research and development, training, distribution, and retail sale of medical and recreational marijuana in the United States and Canada. Medican Enterprises, Inc. was founded in 1988 and is headquartered in Las Vegas, Nevada.
